We Claim:

1. A compound having the formula



or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, for treatment of a hyperproliferative disorder.

3. A pharmaceutical composition comprising a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

4. A pharmaceutical composition as claimed in claim 3, wherein said compound is in an amount equivalent to a dosage amount of from about 0.001 mg per kg body weight per day to about 100 mg per kg body weight per day for treatment of a hyperproliferative disorder.

5. A pharmaceutical composition as claimed in claim 3, wherein said compound is in an amount equivalent to a dosage amount of from about 0.01 mg per kg body weight per day to about 100 mg per kg body weight per day for treatment of a hyperproliferative disorder.

6. A pharmaceutical composition as claimed in claim 3, wherein said compound is in an amount equivalent to a dosage amount of from about 0.1 mg per kg body weight per day to about 10 mg per kg body weight per day for treatment of a hyperproliferative disorder.

7. A pharmaceutical composition as claimed in claim 3, wherein said compound is in an amount equivalent to a dosage amount of about 1 mg per kg body weight per day for treatment of a hyperproliferative disorder.

8. The pharmaceutical composition as claimed in any one of claims 2, 4, 5, 6, and 7, wherein the hyperproliferative disorder is prostate cancer.

9. The pharmaceutical composition as claimed in any one of claims 2, 4, 5, 6, and 7, wherein the hyperproliferative disorder is hormone refractory prostate cancer.

10. The pharmaceutical composition as claimed in any one of claims 2, 4, 5, 6, and 7, wherein the hyperproliferative disorder is hormone sensitive prostate cancer.

11. The pharmaceutical composition as claimed in any one of claims 2, 4, 5, 6, and 7, wherein the hyperproliferative disorder is breast cancer.

12. The pharmaceutical composition as claimed in any one of claims 2, 4, 5, 6, and 7, wherein the hyperproliferative disorder is ovarian cancer.

13. The pharmaceutical composition as claimed in claim 3, wherein the compound is in a form that can be administered as an intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.

14. The pharmaceutical composition as claimed in claim 3, wherein the composition has a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.

15. A method of synthesizing the compound comprising:



mixing N-Methyl-2-fluoro-4-(l,l-dimethyl-cyanomethyl)-aminobenzamide and 4-Isothiocyanato-2-trifluoromethylbenzonitrile in DMF and heating to form a first mixture;

adding an alcohol and an acid to the first mixture to form a second mixture;

refluxing the second mixture; and

cooling the second mixture, combining the second mixture with water and extracting an organic layer;

isolating the compound from the organic layer.

Dated this 13th day of December, 2007

Archana Shanker
Of Anand and Anand Advocates
Agent for the Applicant